EcoDrugPlus

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSPSNG00000012134
Gene Symbol: CCR2
1 Cross references
286 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSPSNG00000009160
Gene Symbol: CCR4
1 Cross references
254 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSPSNG00000012107
Gene Symbol: CCR5
3 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSPSNG00000012574
Gene Symbol: CCR9
3 Cross references
262 Possible Orthologues:

C-X-C Chemokine Receptor Type 2

Ensembl ID : ENSPSNG00000014184
Gene Symbol: LOC116757057
2 Cross references
235 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSPSNG00000007032
Gene Symbol: CXCL8
3 Cross references
183 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSPSNG00000015228
Gene Symbol: CXCR4
3 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSPSNG00000006540
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSPSNG00000019956
Gene Symbol: DNMT1
3 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSPSNG00000004649
Gene Symbol: TOP1
3 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSPSNG00000010629
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSPSNG00000003991
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).